News for Avidity Biosciences, Inc. (RNA)

U.S. stock futures pointed to a mixed opening on Tuesday, June 10, 2025, as investors digest yesterday's market performance and await key economic data. The

Summary Avidity Biosciences Inc (RNA), a biopharmaceutical company focused on developing RNA therapeutics, announced on May 21, 2025, that it has granted non-qu

Avidity Biosciences (RNA) grants inducement equity awards to 16 new non-executive employees. The awards include 71,000 stock options with an exercise pr

**media[626854]**

On May 9, 2025, Avidity Biosciences (RNA) continued to receive positive feedback from analysts as Chardan Capital's Keay Nakae maintained a 'Buy' rating on the

Strengths: Innovative RNA therapeutics platform and strong clinical pipeline.Weaknesses: Heavy reliance on collaboration revenue and significant operating loss

RNA disclosed its first-quarter revenue as $1.6 million, falling short of the anticipated $2.62 million. As of the end of March 2025, the company's cash, cash e

Summary Avidity Biosciences Inc (RNA), a biopharmaceutical company focused on RNA therapeutics, announced its financial results for the first quarter ending Mar

PR NewswireSAN DIEGO, May 8, 2025 On track to deliver key regulatory updates for del-brax and topline data from dose escalation cohorts in the FORTITUDEâ„¢

Avidity Biosciences (RNA) delivered earnings and revenue surprises of -2.27% and 46.68%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Revenue: $1.6 million, below the estimated $1.90 million, reflecting a decrease from $3.5 million in the same period last year.Net Loss: $115.8 million, wideni

We recently published a list of 10 Unstoppable Stocks That Could Double Your Money. In this article, we are going to take a look at where Avidity Biosciences, Inc. (NASDAQ:RNA) stands against other unstoppable stocks that could double your money. Generating significant returns and multiplying their money in the stock market remains a primary goal […]

Generating significant returns and multiplying their money in the stock market remains a primary goal for most investors.

Avidity Biosciences (RNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Wall Street showed mixed performance on Wednesday, April 2, 2025, as investors anxiously awaited President Donald Trump's

Avidity Biosciences, Inc.'s innovative AOC platform and promising clinical programs make it a high-risk, high-reward investment. Read more on RNA stock update.

Avidity Biosciences Inc (RNA), a biopharmaceutical company focused on developing RNA therapeutics, announced on March 21, 2025, that its Human Capital Managemen

PR NewswireSAN DIEGO, March 21, 2025 SAN DIEGO, March 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committ

[url=